# Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

> **NCT01471574** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 549 (actual)

## Conditions studied

- Hepatitis C, Genotype 1

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Ribavirin
- **DRUG:** PEG-Interferon alfa 2a

## Key facts

- **NCT ID:** NCT01471574
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-09
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2016-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01471574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01471574, "Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01471574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*